Summary of Key Points from Conference Call Records Company: Horizon Robotics - **Revenue Performance**: In H1 2025, Horizon Robotics reported revenue of 1.57 billion yuan, a year-on-year increase of 68%, exceeding the expected 1.43 billion yuan. Gross profit was 1.02 billion yuan, a 39% increase year-on-year, but slightly below the expected 1.04 billion yuan [1] - **Business Segmentation**: Revenue from automotive products and solutions reached 780 million yuan, up 250% year-on-year, with shipments of 1.98 million units, a 115% increase. Revenue from automotive licensing and services was 740 million yuan, a 6.9% increase year-on-year [1] - **Market Position**: Horizon Robotics is the first domestic company to achieve a shipment volume of over 10 million units in intelligent driving technology, holding market shares of 32.4% in autonomous driving computing solutions and 45.8% in ADAS front-view integrated machines, both ranking first in the market [1] - **Core Partner**: Zhongke Chuangda, which has a joint venture with Horizon Robotics, reported a non-net profit of 49 million yuan in Q2 2025, a 16-fold increase year-on-year, driven by a 136% increase in revenue from AloT business [1] Industry: Satellite Communication - **Government Initiatives**: On August 27, 2025, the Ministry of Industry and Information Technology released guidelines to promote the development of the satellite communication industry, aiming for over 10 million users of direct satellite connections by 2030 [2] - **Market Developments**: Domestic progress includes China Telecom's plan to promote over 30 direct connection models by May 2025, with annual sales expected to exceed 16 million units [2] - **Key Technologies**: Phased array and beamforming technologies are critical for the implementation of direct satellite communication [3] Industry: Medical and Pharmaceutical - **Policy Framework**: The Ministry of Commerce and Jiangsu Provincial Government issued a development plan for the biopharmaceutical industry on August 27, 2025, focusing on innovation in drugs and high-end medical devices [5] - **Market Size**: In 2024, Jiangsu is expected to approve 352 new drugs, including 13 innovative drugs, leading the nation. The biopharmaceutical cluster in Jiangsu is projected to generate revenue of 454.39 billion yuan in 2024, accounting for 15.3% of the national total [5] - **Core Companies**: Weisi Medical, specializing in non-invasive brain-machine interfaces, and Zhaoyan New Drug, which provides non-clinical research services, are highlighted as key players in the sector [5] Company: Dongtian Microelectronics - **Financial Performance**: In H1 2025, Dongtian Microelectronics reported revenue of 376 million yuan, a 42.29% increase year-on-year, with a non-net profit of approximately 49.78 million yuan, up 109.47% [6] - **Product Expansion**: The company is expanding its product offerings in optical communication and consumer electronics, including camera optical components supplied to Huawei [6] Company: Haosi Automotive Electronics - **Strategic Partnership**: Haosi Automotive Electronics has become a key partner of NVIDIA Jetson Thor, focusing on developing control systems for robotics [7] - **Market Trends**: The value of single-vehicle perception systems is increasing, with prices rising from below 1,000 yuan to 3,000-4,000 yuan per unit due to the proliferation of intelligent driving technologies [7] Company: Yunnan Energy Investment - **Renewable Energy Development**: Yunnan Rongyao New Energy is undergoing compliance checks for its integration into Yunnan Energy Investment, which will increase its renewable energy capacity by nearly 50% [8] - **Financial Projections**: Assuming an annual power generation of 1.2 billion kWh and an electricity price of 0.35 yuan per kWh, the projected annual revenue could reach approximately 420 million yuan, with net profits estimated between 150 million to 200 million yuan [8] Company: Zhongxin Group - **Revenue Growth**: In Q2 2025, Zhongxin Group reported revenue of 1.246 billion yuan, a 161% increase year-on-year, driven by land development and industrial investment [9] - **Operational Metrics**: The company has developed a total area of 3 million square meters in industrial parks, with an occupancy rate of 81% [9] Company: Broadcom Integration - **AI Chip Demand**: Broadcom Integration is benefiting from the growing demand for AI chips in smart terminals, with a focus on Wi-Fi MCU and various AI-integrated chips for applications in AI glasses and toys [10]

Core Insights - Weisi Medical (688580.SH) reported a total revenue of 210 million yuan for the first half of 2025, ranking 72nd among disclosed peers [1] - The company's net profit attributable to shareholders was 69.32 million yuan, with a net cash inflow from operating activities of 64.78 million yuan [1] - The latest debt-to-asset ratio is 8.95%, an increase of 0.48 percentage points from the previous quarter [1] - The gross profit margin decreased to 66.09%, down by 0.56 percentage points from the previous quarter [1] - Return on equity (ROE) stands at 4.28% [1] - The diluted earnings per share (EPS) is 0.72 yuan [1] - Total asset turnover ratio is 0.12 times, ranking 76th among disclosed peers, while inventory turnover ratio is 1.78 times [1] - The number of shareholders is 8,095, with the top ten shareholders holding 66.20 million shares, accounting for 69.13% of the total share capital [1] Shareholding Structure - The largest shareholder is Wang Zhiyu, holding 39.41% of shares [1] - The second-largest shareholder is Hu Ping, with a 16.4% stake [1] - Other notable shareholders include Nanjing Zhida Venture Capital Center (Limited Partnership) at 8.29%, and Shenzhen Yanghe Biomedical Industry Investment Co., Ltd. at 1.80% [1]

（记者 王晓波） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经AI快讯，伟思医疗8月27日晚间发布半年度业绩报告称，2025年上半年营业收入约2.1亿元，同比增 加9.85%；归属于上市公司股东的净利润约6932万元，同比增加39.71%；基本每股收益0.72元，同比增 加38.46%。 每经头条（nbdtoutiao）——世界首例基因编辑猪肺成功移植人体 对话主要参与者：距离临床应用还有 多远？ ...

每经AI快讯，伟思医疗8月27日晚间发布公告称，南京伟思医疗科技股份有限公司于2025年8月27日召 开第四届董事会第五次会议、第四届监事会第五次会议，审议通过了《关于使用暂时闲置自有资金购买 理财产品的议案》，在不影响公司主营业务的正常发展并确保公司经营资金需求的前提下，同意公司自 董事会审议通过之日起12个月内使用不超过人民币10.5亿元的闲置自有资金购买银行保本型、非银行金 融机构保本型理财产品和安全性高、流动性好的中低风险产品。 （记者 王可然） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经头条（nbdtoutiao）——世界首例基因编辑猪肺成功移植人体 对话主要参与者：距离临床应用还有 多远？ ...

格隆汇8月27日丨伟思医疗(688580.SH)发布中报，2025上半年实现营业总收入2.1亿元，同比增长 9.85%；归属母公司股东净利润6932.42万元，同比增长39.71%；基每股收益·0.72元。 ...

Core Viewpoint - Weisi Medical's performance showed steady growth in the first half of 2025, driven by a recovery in hospital procurement demand and the expansion of new business initiatives [2][3]. Financial Performance - In the first half of 2025, Weisi Medical achieved operating revenue of 210 million yuan, a year-on-year increase of 9.85% [2]. - The net profit attributable to shareholders was 69.32 million yuan, reflecting a year-on-year growth of 39.71% [2]. - The net profit excluding non-recurring gains and losses was 63.57 million yuan, up 46.30% year-on-year [2]. - The net cash flow from operating activities reached 64.78 million yuan, marking a significant increase of 101.53% [2]. Business Development - Weisi Medical focuses on high-end rehabilitation equipment across various fields, including pelvic and postpartum rehabilitation, neurological rehabilitation, mental rehabilitation, sports rehabilitation, and pediatric rehabilitation [2]. - The company launched a new generation of physical factor platforms, enhancing the competitiveness of pelvic electrical stimulation products [2]. - Future plans include deepening efforts in women's health and exploring new demands for lifecycle management, aiming to upgrade the pelvic market towards a comprehensive solution combining "pelvic rehabilitation + light medical beauty" [2]. Strategic Initiatives - Weisi Medical is accelerating its layout in laser technology through external acquisitions, establishing a competitive edge in the urology field [3]. - The company is focusing on the medical beauty energy source market, developing innovative products such as picosecond lasers and radiofrequency devices to align with international standards [3]. - Plans to enhance market share in core businesses like pelvic, neurological, and mental rehabilitation are underway, with a focus on clinical applications for products like transcranial magnetic stimulation devices in mental health [3]. Incentive Plans - Weisi Medical introduced a stock incentive plan for 2025-2026, with revenue growth as the sole assessment criterion, targeting an 18% and 40% increase in revenue for 2025 and 2026, respectively, compared to 2024 [4][5].

南京伟思医疗科技股份有限公司 董事会议事规则 第二章 董事会的组成和职权 第三条 董事会由 7 名董事组成，其中独立董事 3 名。董事会设董事长一名， 董事长由董事担任，以全体董事的过半数选举产生或者更换。 第四条 董事会下设董事会办公室，负责处理董事会日常事务。董事会秘书 为董事会办公室负责人，保管董事会印章。 公司聘任证券事务代表协助董事会秘书履行职责。在董事会秘书不能履行职 责时或董事会秘书授权时，证券事务代表应当代为履行职责。在此期间，并不当 然免除董事会秘书对公司信息披露等事务所负有的责任。 第五条 董事会对股东会负责，行使下列职权： 第一章 总则 第一条 为了进一步规范本公司董事会的议事方式和决策程序，促使董事和 董事会有效地履行其职责，提高董事会规范运作和科学决策水平，根据《中华人 民共和国公司法》《中华人民共和国证券法》《上海证券交易所科创板股票上市 规则》等有关规定和《南京伟思医疗科技股份有限公司》（以下简称"《公司章 程》"）的规定，制订本规则。 第二条 董事会应当认真履行有关法律法规和《公司章程》规定的职责，确 保公司依法合规运作，公平对待所有股东，并维护其他利益相关者的合法权益。 （五 ...

第二章 人员组成 第三条 审计委员会成员由董事会任命三名董事组成。审计委员会成员应当 为不在公司担任高级管理人员的董事，其中独立董事应当过半数，委员中至少有 一名独立董事为会计专业人士。 审计委员会成员应当具备履行审计委员会工作职责的专业知识和经验，切实 有效地监督、评估上市公司内外部审计工作，促进公司建立有效的内部控制并提 供真实、准确、完整的财务报告。 南京伟思医疗科技股份有限公司 董事会审计委员会工作细则 第一章 总则 第一条 为强化董事会决策功能，做到事前审计、专业审计，确保董事会对 经理层的有效监督，完善南京伟思医疗科技股份有限公司（以下简称"公司"） 治理结构，根据《中华人民共和国公司法》《上市公司治理准则》《上市公司独立 董事管理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板 上市公司自律监管指引第 1 号——规范运作》《南京伟思医疗科技股份有限公司 章程》（以下简称"《公司章程》"）及其他有关规定，公司特设立董事会审计委员 会，并制定本工作细则。 第二条 董事会审计委员会是董事会下设的专门工作机构，主要负责审核公 司财务信息及其披露、监督及评估内外部审计工作和内部控制。 第四 ...

南京伟思医疗科技股份有限公司 章 程 二〇二五年八月 目 录 | 第一章总 则 . . | | --- | | 第二章 经营宗旨和范围 | | 第三章股份 | | 第一节 股份发行 . | | 第二节 股份增减和回购 . | | 第三节 股份转让 | | 第四章股东和股东会 | | 第一节 股东的一般规定 | | 第二节 控股股东和实际控制人 . | | 第三节 股东会的一般规定 | | 第四节 股东会的召集 . | | 股东会的提案与通知 第五节 | | 股东会的召开 . 第六节 | | 第七节 股东会的表决和决议 | | 第五章 董事和董事会 . | | 董事的一般规定 . 第一节 | | 第二节 董事会 | | 第三节 独立董事 31 | | 第四节 董事会专门委员会 . | | 第六章 高级管理人员 . | | 第七章财务会计制度、利润分配和审计 | | 第一节 财务会计制度 | | 第二节 内部审计 . | | 第三节 会计师事务所的聘任 . | | 第八章 通知和公告 | | 第九章合并、分立、增资、减资、解散和清算 . | | 第一节 合并、分立、增资和减资 | | 第二节 解散和清算 | | ...

南京伟思医疗科技股份有限公司 独立董事工作制度 第一章 总则 第一条 为进一步完善南京伟思医疗科技股份有限公司（以下简称"公司" 或"本公司"）的法人治理结构及公司董事会结构，强化对内部董事及经理层的 约束和激励机制，保护中小股东及利益相关者的利益，促进公司的规范运作，根 据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司独立董事管 理办法》《上海证券交易所科创板股票上市规则》（以下简称"《科创板上市规则》"）、 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》（以下简 称"《规范运作指引》"）等法律、行政法规、部门规章及规范性文件和《南京伟 思医疗科技股份有限公司章程》（以下称"《公司章程》"）的有关规定，制定本制 公司可以根据需要在董事会中设置提名、薪酬与考核、战略等专门委员会。 提名委员会、薪酬与考核委员会中独立董事应当过半数并担任召集人。 第二章 独立董事的任职资格 度。 第二条 独立董事是指不在本公司担任除董事外的其他职务，并与公司及其 主要股东、实际控制人不存在直接或间接利害关系，或者其他可能影响其进行独 立客观判断关系的董事。 独立董事应当独立履行职责，不受公司及 ...